Celgene spondylitis drug misses main goal in late-stage study

July 9 Wed Jul 9, 2014 7:28am EDT

July 9 (Reuters) - Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.

Patients suffering from ankylosing spondylitis who were treated with the drug, Otezla, failed to show statistically significant response compared to those on a placebo, the company said.

However, an independent data monitoring committee recommended that the study should continue unchanged. (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.